Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Progress in medical treatment for glaucoma]

I Azuma1

  • 1Department of Ophthalmology, Osaka Medical College.

Nippon Ganka Gakkai Zasshi
|December 1, 1993
PubMed
Summary

This study investigated treatments for low-tension glaucoma (LTG), finding that adrenergic alpha-1 blockers and prostaglandin compounds effectively reduce intraocular pressure and preserve visual fields in LTG patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Injection of cell-wall skeleton of Mycobacterium bovis BCG draining to a sentinel lymph node eliminates both lymph node metastases and the primary transplanted tumor.

Drug discoveries & therapeutics·2012
Same author

Immune response against cell-wall skeleton of Mycobacterium bovis BCG at the inoculation site and peripheral lymphoid organs.

Drug discoveries & therapeutics·2012
Same author

Phagocytosis plays a dual role in activating dendritic cells; digestive production of active Toll-like receptor ligands and cooperation with Toll-like receptor signaling.

Drug discoveries & therapeutics·2012
Same author

Dorzolamide, a topical carbonic anhydrase inhibitor: a two-week dose-response study in patients with glaucoma or ocular hypertension.

Journal of glaucoma·2009
Same author

Two receptor theory in innate immune activation: studies on the receptors for bacillus Culmet Guillen-cell wall skeleton.

Archivum immunologiae et therapiae experimentalis·2001
Same author

Interferon gamma-producing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCG cell wall skeleton.

International immunopharmacology·2001

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Glaucoma treatment traditionally focuses on lowering intraocular pressure (IOP).
  • Improving intraocular blood flow is also crucial for managing glaucoma.
  • Prevalence of open-angle glaucoma in Japanese adults over 40 is 2.62%, with low-tension glaucoma (LTG) comprising a significant portion.

Purpose of the Study:

  • To evaluate the effects of anti-glaucoma agents on choroidal blood flow.
  • To investigate the role of endothelin-1 (ET-1) in glaucoma pathogenesis.
  • To assess the therapeutic efficacy of bunazosin hydrochloride in LTG patients.

Main Methods:

  • Examined effects of isopropyl unoprostone and bunazosin hydrochloride on rabbit choroidal blood flow.
  • Investigated endothelin-1's impact on IOP, intraocular circulation, and visual function in rabbits.
  • Measured plasma ET-1 concentrations in glaucoma patients and conducted a one-year clinical trial of bunazosin hydrochloride for LTG.

Main Results:

  • Isopropyl unoprostone and bunazosin hydrochloride increased choroidal blood flow in rabbits.
  • Endothelin-1 significantly reduced IOP and choroidal/optic nerve head blood flow in rabbits, effects modulated by calcium channel and alpha-1 blockers.
  • Elevated ET-1 plasma levels were observed in LTG patients.
  • Bunazosin hydrochloride treatment for one year in LTG patients demonstrated satisfactory maintenance of visual fields and IOP reduction.

Conclusions:

  • Adrenergic alpha-1 blockers and prostaglandin compounds are advisable for reducing glaucomatous damage.
  • Endothelin-1 plays a role in LTG pathogenesis.
  • Bunazosin hydrochloride shows clinical utility in managing LTG.

Related Experiment Videos